Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Daptomycin.

David A Enoch1, Jeanine M Bygott, Marie-Louise Daly

  • 1Clinical Microbiology and Public Health Laboratory, Health Protection Agency East of England, Papworth Hospital, Papworth Everard, Cambridgeshire, UK.

The Journal of Infection
|July 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whole-genome sequencing to investigate the prevalence and transmission of multidrug-resistant Gram-negative pathogens in an adult intensive care unit in the UK.

Microbial genomics·2026
Same author

Use of TaqMan array card to investigate bacterial isolates in diabetic foot ulcers.

Journal of medical microbiology·2026
Same author

Travel-associated carbapenem-resistant organisms at a time of increasing geopolitical instability: a UK perspective.

The Journal of hospital infection·2025
Same author

Refractory fungal infection: Three case reports highlighting good practice.

Medical mycology case reports·2025
Same author

Effectiveness, Safety, and Patterns of Real-World Isavuconazole Use in Europe (2015-2019).

Infectious diseases and therapy·2024
Same author

Exploring European Consensus About the Remaining Treatment Challenges and Subsequent Opportunities to Improve the Management of Invasive Fungal Infection (IFI) in the Intensive Care Unit.

Mycopathologia·2024

Daptomycin is an effective antibiotic for Gram-positive infections, including resistant strains. While antimicrobial resistance is rising, daptomycin remains safe and well-tolerated, with further research needed for specific conditions.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Increasing prevalence of resistant Gram-positive pathogens.
  • Concerns regarding glycopeptide effectiveness against Staphylococcus aureus infections.
  • Emergence of multi-resistant bacterial strains necessitates alternative treatments.

Purpose of the Study:

  • To review the efficacy and safety of daptomycin as a treatment for Gram-positive bacterial infections.
  • To highlight daptomycin's role in managing infections caused by resistant pathogens.
  • To discuss current and potential future applications of daptomycin.

Main Methods:

  • Review of existing clinical data and licensed indications for daptomycin.
  • Analysis of daptomycin's pharmacokinetic and pharmacodynamic properties.

Related Experiment Videos

  • Assessment of safety and tolerability profiles based on clinical use.

    • Main Results:

    • Daptomycin demonstrates activity against Gram-positive organisms, including multi-resistant strains.
    • Licensed for complicated skin and soft tissue infections (4mg/kg daily) and S. aureus bacteraemia/endocarditis (6mg/kg daily).
    • Generally safe and well-tolerated at current dosing regimens, with relatively rare antimicrobial resistance.

    Conclusions:

    • Daptomycin is a valuable therapeutic option for Gram-positive infections, especially those involving resistant organisms.
    • Further investigation is warranted for its use in osteomyelitis, septic arthritis, and combination therapies.
    • Continued monitoring of antimicrobial resistance patterns is crucial.